Bristol-myers Squibb Pharma Company

Bristol-myers Squibb Compnay

Robert A Copeland

Micky Daniel Tortorella

Michael A Pratta

Elizabeth C Arner

Ruiqin Liu

Carl P Decicco

Timothy C Burn

Ronald L Magolda

James M Trzaskos

Fude Yang

Kimberly A Solomon

Jeffrey Allan Miller

Gary L Davis

Andrew Paul Combs

Eddy W Yue

Claudio Mapelli

Michael G Kornacker

Wei Han

Douglas James Riexinger

Ving G Lee

C Anne Higley

Susan V DiMeo

Joseph Hendrick

Zhihong Lai

Charles F Albright

Randine L Dowling

Mark Richard Witmer

Nilsa R Graciani

Jovita Marcinkeviciene

Pearl S Huang

William Metzler

The present invention provides peptides that specifically bind to BACE at a newly discovered exosite. The invention also provides methods for identifying peptides that bind to a BACE exosite. The invention further provides methods for identifying compounds that bind to a BACE exosite and modulate BACE activity. In another aspect, the invention provides methods for treating or preventing neurodegenerative disorders such as Alzheimer's disease by administering compounds that bind to a BACE exosite and modulate BACE activity.

Beta secretase exosite binding peptides and methods for identifying beta secretase modulators

This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity.

Assays and peptide substrate for determining aggrecan degrading metallo protease activity

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same

This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.

Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu -Ala . The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Aggrecan degrading metallo proteases

Nucleic acids encoding aggrecan degrading metallo proteases

Growing community of inventors

Hockessin, DE, United States of America

Robert A Copeland